AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Daiichi Sankyo's environmental, social, and governance risks are included in our valuation. Like any other pharmaceutical company, access to basic services (tied to drug pricing) is an ESG risk ...

Three years earlier, Daiichi Sanko snapped up Germany’s U3 Pharma for €150 million ($235 million at the time but $190.5 million today). That deal boosted Daiichi Sankyo’s pipeline with U3 ...

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-3939 is comprised of a humanized anti-TA-MUC1 antibody, attached to a number of topoisomerase I inhibitor payloads (an exatecan ...